Published in Assay Drug Dev Technol on June 01, 2007
Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin α1-antitrypsin Z. PLoS One (2010) 1.62
Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Assay Drug Dev Technol (2008) 1.14
Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments. Assay Drug Dev Technol (2010) 1.10
Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library. Assay Drug Dev Technol (2009) 1.02
Characterisation of the PTEN inhibitor VO-OHpic. J Chem Biol (2010) 1.01
Redox cycling compounds generate H2O2 in HTS buffers containing strong reducing reagents--real hits or promiscuous artifacts? Curr Opin Chem Biol (2010) 0.98
Pharmacological targeting of the mitochondrial phosphatase PTPMT1. J Pharmacol Exp Ther (2010) 0.92
Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2. Assay Drug Dev Technol (2010) 0.82
Development and validation of a high-content screening assay to identify inhibitors of cytoplasmic dynein-mediated transport of glucocorticoid receptor to the nucleus. Assay Drug Dev Technol (2012) 0.81
HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines. Assay Drug Dev Technol (2015) 0.80
Reducing agents affect inhibitory activities of compounds: results from multiple drug targets. Anal Biochem (2012) 0.79
In vivo structure-activity relationship studies support allosteric targeting of a dual specificity phosphatase. Chembiochem (2014) 0.78
High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions. Assay Drug Dev Technol (2014) 0.77
Development and validation of a robust and sensitive assay for the discovery of selective inhibitors for serine/threonine protein phosphatases PP1α (PPP1C) and PP5 (PPP5C). Assay Drug Dev Technol (2014) 0.76
Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC Screen. Assay Drug Dev Technol (2016) 0.75
A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity. J Pharmacol Exp Ther (2017) 0.75
Epigenetic assays for chemical biology and drug discovery. Clin Epigenetics (2017) 0.75
Chemical genetics of Plasmodium falciparum. Nature (2010) 5.52
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res (2009) 3.59
Metamorphic enzyme assembly in polyketide diversification. Nature (2009) 2.64
Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nat Chem Biol (2007) 2.57
An experimental survey of the transition between two-state and downhill protein folding scenarios. Proc Natl Acad Sci U S A (2008) 2.57
Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene (2003) 2.57
microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res (2009) 2.32
When NRF2 talks, who's listening? Antioxid Redox Signal (2010) 2.32
Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther (2004) 2.25
Automated image-based phenotypic analysis in zebrafish embryos. Dev Dyn (2009) 2.11
Targeting mitochondria. Acc Chem Res (2008) 2.03
Cytochrome c/cardiolipin relations in mitochondria: a kiss of death. Free Radic Biol Med (2009) 2.00
Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther (2007) 1.95
Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat Chem Biol (2009) 1.88
A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J Med Chem (2005) 1.80
The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem (2004) 1.75
Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. J Biol Chem (2008) 1.74
Nanoparticles in cellular drug delivery. Bioorg Med Chem (2009) 1.70
Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin α1-antitrypsin Z. PLoS One (2010) 1.62
Lipidomics identifies cardiolipin oxidation as a mitochondrial target for redox therapy of brain injury. Nat Neurosci (2012) 1.58
Small molecule modulators of endogenous and co-chaperone-stimulated Hsp70 ATPase activity. J Biol Chem (2004) 1.51
Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J Biol Chem (2006) 1.47
Post-translational import of protein into the endoplasmic reticulum of a trypanosome: an in vitro system for discovery of anti-trypanosomal chemical entities. Biochem J (2009) 1.46
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther (2005) 1.46
A precursor-specific role for Hsp40/Hsc70 during tail-anchored protein integration at the endoplasmic reticulum. J Biol Chem (2008) 1.44
HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev Technol (2007) 1.40
Halenaquinone and xestoquinone derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp. Bioorg Med Chem (2005) 1.40
A mitochondria-targeted nitroxide/hemigramicidin S conjugate protects mouse embryonic cells against gamma irradiation. Int J Radiat Oncol Biol Phys (2008) 1.39
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol (2008) 1.38
22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol Chem (2003) 1.37
Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase. J Biol Chem (2002) 1.37
Structural requirements for optimized delivery, inhibition of oxidative stress, and antiapoptotic activity of targeted nitroxides. J Pharmacol Exp Ther (2006) 1.36
Polyketide decarboxylative chain termination preceded by o-sulfonation in curacin a biosynthesis. J Am Chem Soc (2009) 1.35
The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. J Biol Chem (2005) 1.31
The substrate recognition domains of the N-end rule pathway. J Biol Chem (2008) 1.31
Diallyl trisulfide-induced G(2)-M phase cell cycle arrest in human prostate cancer cells is caused by reactive oxygen species-dependent destruction and hyperphosphorylation of Cdc 25 C. Oncogene (2005) 1.30
Two strategies for the development of mitochondrion-targeted small molecule radiation damage mitigators. Int J Radiat Oncol Biol Phys (2011) 1.29
PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells. Cancer Res (2007) 1.28
Binding of a small molecule at a protein-protein interface regulates the chaperone activity of hsp70-hsp40. ACS Chem Biol (2010) 1.28
Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta (2010) 1.25
Microbial and chemical transformation studies of the bioactive marine sesquiterpenes (S)-(+)-curcuphenol and -curcudiol isolated from a deep reef collection of the Jamaican sponge Didiscus oxeata. J Nat Prod (2002) 1.22
Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol Pharmacol (2002) 1.20
Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility. BMC Chem Biol (2010) 1.20
Oxidative lipidomics of hyperoxic acute lung injury: mass spectrometric characterization of cardiolipin and phosphatidylserine peroxidation. Am J Physiol Lung Cell Mol Physiol (2010) 1.19
Dual-specificity phosphatases as targets for antineoplastic agents. Nat Rev Drug Discov (2002) 1.19
Dual specificity protein phosphatases: therapeutic targets for cancer and Alzheimer's disease. Annu Rev Pharmacol Toxicol (2005) 1.18
Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds. ACS Chem Biol (2009) 1.18
Stereochemistry of oxachlorocarbene S(N)i reactions. Org Lett (2005) 1.18
Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. J Med Chem (2009) 1.14
Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. PLoS Negl Trop Dis (2009) 1.14
Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Assay Drug Dev Technol (2008) 1.14
The mitochondria-targeted nitroxide JP4-039 augments potentially lethal irradiation damage repair. In Vivo (2009) 1.14
Mitochondrial-derived reactive oxygen species (ROS) play a causal role in aging-related intervertebral disc degeneration. J Orthop Res (2013) 1.13
Mitochondria-targeted disruptors and inhibitors of cytochrome c/cardiolipin peroxidase complexes: a new strategy in anti-apoptotic drug discovery. Mol Nutr Food Res (2009) 1.13
Hemigramicidin-TEMPO conjugates: novel mitochondria-targeted anti-oxidants. Biochem Pharmacol (2007) 1.13
Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease. Cell Rep (2012) 1.12
Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101. J Oncol (2011) 1.11
In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J Pharmacol Exp Ther (2010) 1.11
TargetHunter: an in silico target identification tool for predicting therapeutic potential of small organic molecules based on chemogenomic database. AAPS J (2013) 1.11
Identification of survival genes in human glioblastoma cells by small interfering RNA screening. Mol Pharmacol (2009) 1.11
A target-based high throughput screen yields Trypanosoma brucei hexokinase small molecule inhibitors with antiparasitic activity. PLoS Negl Trop Dis (2010) 1.10
Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments. Assay Drug Dev Technol (2010) 1.10
A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. Mol Cancer Ther (2008) 1.10
Electrostatic versus steric effects in peptidomimicry: synthesis and secondary structure analysis of gramicidin S analogues with (E)-alkene peptide isosteres. J Am Chem Soc (2005) 1.10
Pyrimidinone-peptoid hybrid molecules with distinct effects on molecular chaperone function and cell proliferation. Bioorg Med Chem (2007) 1.09
Mitochondrial targeting of electron scavenging antioxidants: Regulation of selective oxidation vs random chain reactions. Adv Drug Deliv Rev (2009) 1.09
Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone pharmacophore. ChemMedChem (2008) 1.09
Targeted deletion of the metastasis-associated phosphatase Ptp4a3 (PRL-3) suppresses murine colon cancer. PLoS One (2013) 1.07
Select pyrimidinones inhibit the propagation of the malarial parasite, Plasmodium falciparum. Bioorg Med Chem (2009) 1.07
Evaluating beta-turn mimics as beta-sheet folding nucleators. Proc Natl Acad Sci U S A (2009) 1.07
Treatment with a novel hemigramicidin-TEMPO conjugate prolongs survival in a rat model of lethal hemorrhagic shock. Ann Surg (2007) 1.06
Stochastic voyages into uncharted chemical space produce a representative library of all possible drug-like compounds. J Am Chem Soc (2013) 1.05
Cellular analysis of disorazole C and structure-activity relationship of analogs of the natural product. Chem Biol Drug Des (2006) 1.05
Effector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity. Chem Biol (2013) 1.05
Intraesophageal administration of GS-nitroxide (JP4-039) protects against ionizing irradiation-induced esophagitis. In Vivo (2010) 1.05
Fluorous Synthesis: Fluorous Protocols for the Ugi and Biginelli Multicomponent Condensations. J Org Chem (1997) 1.04
Redox regulation of Cdc25B by cell-active quinolinediones. Mol Pharmacol (2005) 1.04
Use of transcriptional synergy to augment sensitivity of a splicing reporter assay. RNA (2006) 1.04
A microwave assisted intramolecular-furan-Diels-Alder approach to 4-substituted indoles. Chem Commun (Camb) (2008) 1.04
Terminal alkene formation by the thioesterase of curacin A biosynthesis: structure of a decarboxylating thioesterase. J Biol Chem (2011) 1.03
Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library. Assay Drug Dev Technol (2009) 1.02